This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Ophthalmol. 2002;120:1756-1761.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Melanoma-associated retinopathy (MAR) is a paraneoplastic retinopathy that occurs predominantly in males as a distal effect induced by the immune system's response to a cutaneous malignant melanoma (CMM).¹ Onset and survival differ markedly, with associated vision problems occurring, on average, 3.6 years (range, 2 months to 19 years) following the diagnosis of CMM, and 1.9 years (range, 1 month to 15 years) subsequent to the finding of metastases. Survival time following the diagnosis of CMM is 5.9 years on average, ranging from 1 to 19.5 years.¹ The MAR syndrome typically manifests as a sudden onset of disabling glare or night blindness that is thought to result from the production of autoantibodies reactive with retinal depolarizing bipolar cells.² While the physical appearance of the retina is frequently normal, changes in the retinal pigment epithelium (RPE), such as a slight mottling, have been reported^{1, 3} together with optic disc pallor, retinal vessel attenuation, . . . [Full Text of this Article]

Report of a Case

Comment

Corresponding author: Anja M. Palmowski, MD, Department of Ophthalmology, Saarland University Hospital, D-66421 Homburg/Saar, Germany (e-mail: auapal@med-rz.uni-sb.de).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Autoantibodies Against Bestrophin in a Patient With Vitelliform Paraneoplastic Retinopathy and a Metastatic Choroidal Malignant Melanoma
Eksandh et al.
Arch Ophthalmol 2008;126:432-435.
FULL TEXT